Expression of genes for drug transporters in the human female genital tract and modulatory effect of antiretroviral drugs

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Hijazi, Karolin ^a   Cuppone, Anna M ^b   Smith, Kieron ^a   Stincarelli, Maria A ^c   Ekeruche Makinde, Julia ^d   De Falco, Giulia ^b   Hold, Georgina L ^a   Shattock, Robin ^d   Kelly, Charles G ^e   Pozzi, Gianni ^b,c   Iannelli, Francesco ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF SIENA   (Italy)

^c MICROBIOTEC Srl   (Italy)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTIRETROVIRUS AGENT; BREAST CANCER RESISTANCE PROTEIN; DAPIVIRINE; DARUNAVIR; MICROBICIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 5; NUCLEOSIDE; NUCLEOTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARRIER PROTEIN; PYRIMIDINE DERIVATIVE; TMC120-R147681;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; FEMALE; FEMALE GENITAL SYSTEM; GENE EXPRESSION; HELA CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MODULATION; PROTEIN EXPRESSION; TRANSPORT KINETICS; UPREGULATION; UTERINE CERVIX; VAGINA EPITHELIUM; VIRUS TRANSMISSION; BIOSYNTHESIS; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; ORGAN CULTURE TECHNIQUE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; VAGINA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CELL LINE, TUMOR; CERVIX UTERI; DARUNAVIR; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; PYRIMIDINES; TENOFOVIR; VAGINA;

EID: 84939240024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131405     Document Type: Article

References (44)

1. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008; 359: 463-472. doi:10.1056/NEJMoa0707957 PMID:18669425
2. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL- 1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002; 360: 971-977. PMID:12383665
3. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007; 2: e1312. PMID:18091987
4. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebocontrolled trial. Lancet. 2008; 372: 1977-1987. doi:10.1016/S0140-6736(08)61842-5 PMID:19059048
5. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double- blind, parallel-group trial. Lancet. 2010; 376: 1329-1337. doi:10.1016/S0140-6736(10)61086-0 PMID:20851460
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329: 1168-1174. doi:10.1126/science.1193748 PMID:20643915
7. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372: 509-518. doi:10. 1056/NEJMoa1402269 PMID:25651245
8. Rees H, Delany-Moretlwe S, Baron D, Lombard C, Gray G, Myer L, et al. FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. Conference on Retroviruses and Opportunistic Infections (CROI). February 23-26, 2015 | Seattle, Washington: Abstract 26LB.
9. Kelly CG, Shattock RJ. Specific microbicides in the prevention of HIV infection. J Intern Med. 2011; 270: 509-519. doi:10.1111/j.1365-2796.2011.02454.x PMID:21917029
10. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007; 26: 257-270. PMID:17306567
11. Zhou T, Hu M, Pearlman A, Patton D, Rohan L. Expression and Localization of P-Glycoprotein, Multidrug Resistance Protein 4, and Breast Cancer Resistance Protein in the Female Lower Genital Tract of Human and Pigtailed Macaque. AIDS Res Hum Retroviruses. 2014.
12. Zhou T, Hu M, Cost M, Poloyac S, Rohan L. Expression of Transporters and Metabolizing Enzymes in the Female Lower Genital Tract: Implications for Microbicide Research. AIDS Res Hum Retroviruses. 2013.
13. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J, et al. Cell entry and export of nucleoside analogues. Virus Res. 2005; 107: 151-164. PMID:15649561
14. Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010; 31: 22-35. doi:10.1016/j.tips.2009.10.001 PMID:20004485
15. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007; 59: 238-245. PMID:17202245
16. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos. 2007; 35: 340-344. PMID:17172311
17. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010; 40: 163-176. doi:10.3109/00498250903509375 PMID:20102298
18. Tempestilli M, Gentilotti E, Tommasi C, Nicastri E, Martini F, De Nardo P, et al. Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors. Int Immunopharmacol. 2013; 16: 492-497. doi:10.1016/j.intimp.2013.05.003 PMID:23707228
19. Fichorova RN, Rheinwald JG, Anderson DJ. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissuespecific differentiation proteins. Biol Reprod. 1997; 57: 847-855. PMID:9314589
20. Konig SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010; 65: 2319-2328. doi:10.1093/jac/dkq324 PMID:20817741
21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3: RESEARCH0034. PMID:12184808
22. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3: 1101-1108. PMID:18546601
23. Gali Y, Delezay O, Brouwers J, Addad N, Augustijns P, Bourlet T, et al. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother. 2010; 54: 5105-5114. doi:10.1128/AAC.00456-10 PMID:20921308
24. Hubatsch I, Ragnarsson EG, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007; 2: 2111-2119. PMID:17853866
25. Gunawardana M, Mullen M, Moss JA, Pyles RB, Nusbaum RJ, Patel J, et al. Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One. 2013; 8: e77340. doi:10.1371/journal.pone.0077340 PMID:24143220
26. Grammen C, Baes M, Haenen S, Verguts J, Augustyns K, Zydowsky T, et al. Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits. Mol Pharm. 2014; 11: 4405-4414. doi:10.1021/mp5005004 PMID:25327902
27. International Partnership for Microbicides. 2015. The Ring Study. http://www.ipmglobal.org/the-ringstudy.
28. Microbicides Trial Network. 2015. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women. http://www.mtnstopshiv.org/studies/3614.
29. Murphy DJ, Desjardins D, Dereuddre-Bosquet N, Brochard P, Perrot L, Pruvost A, et al. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. J Antimicrob Chemother. 2014; 69: 2477-2488. doi:10.1093/jac/dku160 PMID:24862093
30. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001; 120: 51-57. PMID:11323161
31. Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochem Biophys Res Commun. 2013; 439: 221-227. doi:10.1016/j.bbrc.2013.08.054 PMID:23981805
32. Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance- associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007; 60: 987-993. PMID:17890284
33. Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, Farinotti R, et al. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses. 2008; 24: 1147-1154. doi:10.1089/aid.2007.0022 PMID:18729774
34. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS. 2005; 19: 2097-2102. PMID:16284458
35. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A. 2000; 97: 7476-7481. PMID:10840050
36. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006; 50: 3297-3304. PMID:17005808
37. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, et al. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009; 32: 1588-1593. PMID:19721237
38. Neumanova Z, Cerveny L, Ceckova M, Staud F. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS. 2014; 28: 9-17. doi:10.1097/QAD.0000000000000112 PMID:24413260
39. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS. 2011; 25: 1971-1979. doi:10.1097/QAD.0b013e32834b3629 PMID:21811139
40. Cost M, Dezzutti CS, Clark MR, Friend DR, Akil A, Rohan LC. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother. 2012; 56: 3058-3066. doi:10.1128/AAC.06284-11 PMID:22430977
41. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010; 62: 1-96. doi:10.1124/pr.109.002014 PMID:20103563
42. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007; 51: 3498-3504. PMID:17664327
43. Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother. 2009; 53: 896-902. doi:10.1128/AAC.00733-08 PMID:19075072
44. Plasschaert SL, de Bont ES, Boezen M, vander Kolk DM, Daenen SM, Faber KN, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res. 2005; 11: 8661-8668. PMID:16361551